POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

New ASCO/CCO Prostate Cancer Guidelines

The right time for American Society of Clinical Oncology and Cancer Care Ontario on metastatic castration-resistant prostate cancer.

BELEODAQ (belinostat) for Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

This slideshow reviews drug information for BELEODAQ (belinostat), indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL).

Immune Therapy for Metastatic Renal Carcinoma

Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.

Prostate Cancer and Its Link to Male Pattern Baldness

A recent study published in the Journal of Clinical Oncology links male pattern baldness with elevated risk of aggressive prostate cancer.

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer

This review considers the molecular mechanisms associated with HER2 resistance and evaluates the evidence of evolving strategies to treat patients with HER2-resistant breast cancer.

New Targeted Approaches Changing the Management of Lung Cancer

ALCHEMIST to screen 8,000 patients with early-stage lung cancer, randomly assigning patients with EGFR mutations or rearrangement of the ALK gene.

New Cancer Progress Report From AACR

A new report from the American Association for Cancer Research highlights the need for increased federal funding of cancer research.

CTA Social Media Survey

CTA would like to know how you use social media services to make sure we’re effectively delivering the content you love.

Featured Videos

Viewpoints & Feature Articles

New ASCO/CCO Prostate Cancer Guidelines Emphasize Quality of Life

New ASCO/CCO Prostate Cancer Guidelines Emphasize Quality of Life

The right time for American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) on metastatic castration-resistant prostate cancer.

Certain Kind of Baldness at Age 45 Linked to Increased Risk of Prostate Cancer

Certain Kind of Baldness at Age 45 Linked to Increased Risk of Prostate Cancer

A recent study published in the Journal of Clinical Oncology links male pattern baldness with elevated risk of aggressive prostate cancer.

ALCHEMIST to Treat Early-Stage Lung Cancer With Erlotinib and Crizotinib

ALCHEMIST to Treat Early-Stage Lung Cancer With Erlotinib and Crizotinib

ALCHEMIST to screen 8,000 patients with early-stage lung cancer, randomly assigning patients with EGFR mutations or rearrangement of the ALK gene.

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer

Human epidermal growth factor receptor-2 is overexpressed in up to 30% of breast cancers; indicative of poor prognosis.

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success.

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.



From Oncology Nurse Advisor

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs